Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, TRADE SHOWS/SEMINARS/WEBINARS

Arbutus to Participate in Two Upcoming Investor Conferences


WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:

To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: [email protected]



These press releases may also interest you

at 19:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...

at 14:00
Revolutionising Vascular Access Care for Critically Ill Newborns and Children Key Points: FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access...

at 10:19
February 15, 2025 Product:  All Dressed Pizza (U Bake), Super Pizza (U Bake) Issue:  Food - Allergen - Mustard Distribution:  Saskatchewan See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 07:10
The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel). This marks the first successful treatment of its kind...

at 07:00
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained...

at 07:00
Independent Pharmacy Cooperative (IPC), the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic partnership...



News published on and distributed by: